Skip to content
Sinecatechins
Veregen (sinecatechins) is an unknown pharmaceutical. Sinecatechins was first approved as Veregen on 2006-10-31.
Download report
Favorite
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
Veregen
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Sinecatechins
Tradename
Company
Number
Date
Products
VEREGENANI PHARMSN-021902 RX2006-10-31
1 products, RLD, RS
Labels
FDA
EMA
Brand Name
Status
Last Update
veregenNew Drug Application2022-11-10
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
Patent
Expires
Flag
FDA Information
Sinecatechins, Veregen, Ani Pharms
78586622026-10-02DPU-172
97704062025-07-12DPU-172
ATC Codes
D: Dermatologicals
D06: Antibiotics and chemotherapeutics for dermatological use
D06B: Chemotherapeutics for topical use
D06BB: Antivirals, topical
D06BB12: Sinecatechins
HCPCS
No data
Clinical
Clinical Trials
500 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
AnesthesiaD0007583510192964
General anesthesiaD00076812581227
Postoperative painD010149G89.1811161221
Emergence deliriumD0000712576915
DeliriumD003693R41.0116614
Postoperative cognitive complicationsD000079690212610
Breast neoplasmsD001943EFO_0003869C501359
Postoperative nausea and vomitingD020250EFO_0004888437
Respiratory distress syndromeD012128EFO_1000637J804217
HypotensionD007022EFO_0005251I95336
Show 104 more
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Postoperative complicationsD011183134
AnalgesiaD000698213
Respiratory insufficiencyD012131HP_0002093J96.9213
Non-small-cell lung carcinomaD002289112
Kidney transplantationD016030112
Drug-related side effects and adverse reactionsD064420T88.7112
Intratracheal intubationD007442112
Aortic valve insufficiencyD001022EFO_0007148112
Mitral valve insufficiencyD008944HP_0001653112
Esophageal neoplasmsD004938C1511
Show 20 more
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Inguinal herniaD006552HP_0000023K40123
Opioid-related disordersD009293EFO_0005611F11123
Substance-related disordersD019966EFO_0003890F13123
PhimosisD010688EFO_1001104N47.1112
ParaphimosisD010263EFO_1001086N47.2112
BalanitisD001446EFO_1000833N48.1112
CryptorchidismD003456EFO_0004562Q53.1112
Lung injuryD055370S27.301112
Atrial fibrillationD001281EFO_0000275I48.01112
Radical mastectomyD015409111
Show 9 more
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
InflammationD007249213
Chronic kidney failureD007676EFO_0003884N18.611
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Inhalation anesthesiaD00076944
Urinary bladder neoplasmsD001749C6733
Myocardial ischemiaD017202EFO_1001375I20-I2533
Cerebral palsyD002547G8022
Operative surgical proceduresD01351422
Mitochondrial diseasesD028361EFO_000059122
HemiarthroplastyD06278522
Biliary atresiaD001656EFO_0004217Q44.222
RhytidoplastyD01536111
Alzheimer diseaseD000544EFO_0000249F0311
Show 82 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameSINECATECHINS
INN
Description
Sinecatechins (USAN, trade names Veregen and Polyphenon E) is a specific water extract of green tea leaves from Camellia sinensis that is the active ingredient in an ointment approved by the FDA in 2006 as a botanical drug to treat genital warts. Sinecatechins are mostly catechins, 55% of which is epigallocatechin gallate. It was the first botanical drug approved by the US FDA.
Classification
Unknown
Drug class
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
Identifiers
PDB
CAS-ID
RxCUI
ChEMBL IDCHEMBL1201723
ChEBI ID
PubChem CID
DrugBank
UNII ID
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 230 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
5,428 adverse events reported
View more details